Intézmény

IRCCS Humanitas Research Hospital

Rozzano, OlaszországHonlap

Más néven: Istituto Clinico Humanitas IRCCS

254futó vizsgálat
160lezárt vizsgálat
25 081publikáció (OpenAlex)

Futó vizsgálatok

Még nem toboroz
Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.
NCT07927777· 3. fázis· Istituto Oncologico Veneto IRCCS· Forrás
Még nem toboroz
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175· 2. fázis· Aimmune Nestlé Health Science US R&D, LLC· Forrás
Még nem toboroz
Nutritional Supplementation to Improve Colorectal Cancer Surgery
NCT07599501· Istituto Clinico Humanitas· Forrás
Toboroz
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· 3. fázis· Kardigan, Inc.· Forrás
Toboroz
Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM
NCT07730203· Istituto Clinico Humanitas· Forrás
Még nem toboroz
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
2025-522084-15-00· 2/3. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors
NCT07635641· Istituto Clinico Humanitas· Forrás
Toboroz
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· 1. fázis· Eli Lilly and Company· Forrás
Toboroz
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· 2/3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.
NCT07577115· Istituto Clinico Humanitas· Forrás
Toboroz
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
NCT07413523· Istituto Clinico Humanitas· Forrás
Toboroz
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723· 2/3. fázis· Kardigan, Inc.· Forrás
Még nem toboroz
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
NCT07207785· 2. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Még nem toboroz
Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction
NCT07358247· Istituto Clinico Humanitas· Forrás
Még nem toboroz
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
NCT07381777· 2. fázis· Gruppo Oncologico Italiano di Ricerca Clinica· Forrás
Toboroz
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
NCT07485296· 2. fázis· Gruppo Oncologico del Nord-Ovest· Forrás
Meghívásos bevonás
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668· SafeHeal Inc· Forrás
Még nem toboroz
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
NCT07336641· Fondazione ISIDE· Forrás
Toboroz
Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial
NCT07299357· Istituto Clinico Humanitas· Forrás
Toboroz
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
NCT07330245· AstraZeneca· Forrás
Toboroz
Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment
NCT07393360· Pharmanutra S.p.a.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· 3. fázis· Amgen· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448· 2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
NCT07389265· 3. fázis· University of Campania Luigi Vanvitelli· Forrás
Toboroz
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798· 2. fázis· Amgen· Forrás
Toboroz
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
NCT07073079· AbbVie· Forrás
Toboroz
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Még nem toboroz
Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)
NCT06790251· F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore· Forrás
Toboroz
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· 2. fázis· Pfizer· Forrás
Toboroz
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
NCT06994143· 1. fázis· Cullinan Therapeutics Inc.· Forrás
Meghívásos bevonás
p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging
NCT07603167· Humanitas University· Forrás
Toboroz
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
NCT06462963· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
NCT06949254· Istituto Clinico Humanitas· Forrás
Fut, nem toboroz
Racial Disparities in Acute Stroke
NCT06955442· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Fut, nem toboroz
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
NCT05605899· 3. fázis· Kite Pharma Inc.· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Photon-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis
NCT07790614· Istituto Clinico Humanitas· Forrás
Fut, nem toboroz
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
NCT06716814· 3. fázis· Swedish Orphan Biovitrum· Forrás
Még nem toboroz
Effects of Action Observation Training and Motor Imagery Delivered by Telerehabilitation in Patients with Parkinson's Disease
NCT06814782· Istituto Clinico Humanitas· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
NCT06717126· 2. fázis· iOnctura· Forrás

Showing 50 of 254.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Vastagbélrák19 toboroz
Tüdőrák16 toboroz
Prosztatarák12 toboroz
Gyermekkori daganatok10 toboroz
Gyomor- és nyelőcsőrák10 toboroz
Fej-nyaki daganatok8 toboroz
Áttétes emlőrák6 toboroz
Szarkóma6 toboroz
Crohn-betegség4 toboroz
Hasnyálmirigyrák4 toboroz
Hólyagrák4 toboroz
Máj- és epeúti rák4 toboroz
Rheumatoid arthritis4 toboroz
Glioblasztóma3 toboroz
Hemofília3 toboroz
Méhtestrák3 toboroz
Petefészekrák3 toboroz
Stroke (szélütés)3 toboroz
Akut mieloid leukémia (AML)2 toboroz
Asztma2 toboroz
Bronchiectasis2 toboroz
Colitis ulcerosa2 toboroz
Dermatomyositis and polymyositis (myositis)2 toboroz
Dilated cardiomyopathy2 toboroz
Follikuláris limfóma2 toboroz
Hodgkin-limfóma2 toboroz
Köpenysejtes limfóma2 toboroz
Lupus (SLE)2 toboroz
Melanóma2 toboroz
Neuroendokrin daganatok2 toboroz
Pikkelysömör2 toboroz
Tripla negatív emlőrák2 toboroz
Zsírmáj (MASLD/MASH)2 toboroz
Alopecia areata1 toboroz
Amiloidózis1 toboroz
Aortic stenosis1 toboroz
Arthritis psoriatica1 toboroz
Atópiás dermatitisz (ekcéma)1 toboroz
Cisztás fibrózis1 toboroz
Cytomegalovirus infection1 toboroz
Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
Elhízás1 toboroz
Hidradenitis suppurativa1 toboroz
Idiopátiás tüdőfibrózis1 toboroz
IgA-nefropátia1 toboroz
Immune thrombocytopenia (ITP)1 toboroz
Koszorúér-betegség1 toboroz
Krónikus vesebetegség1 toboroz
Liver cirrhosis1 toboroz
Méhnyakrák1 toboroz
Meningioma1 toboroz
Mezotelióma1 toboroz
Myocarditis1 toboroz
Osteoarthritis1 toboroz
Pajzsmirigyrák1 toboroz
Parkinson-kór1 toboroz
Pitvarfibrilláció1 toboroz
Primer biliáris cholangitis (PBC)1 toboroz
Szívelégtelenség1 toboroz
Ventricular tachycardia1 toboroz
Vesedaganat1 toboroz
Vitiligo1 toboroz

Lezárt vizsgálatok

Lezárult
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
NCT06587451· 3. fázis· H e x a l AG· Forrás
Lezárult
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
2023-505801-17-00· 1. fázis· Swedish Orphan Biovitrum AB (publ)· Forrás
Fut, nem toboroz
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458· 2. fázis· GCP-Service International West GmbH· Forrás
Lezárult
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
2023-508736-62-00· 2. fázis· Cardurion Pharmaceuticals Inc.· Forrás
Lezárult
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis
2023-508679-34-00· 2. fázis· Anaptysbio Inc.· Forrás
Lezárult
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· 2. fázis· Genentech Inc.· Forrás
Lezárult
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
2023-506881-30-00· 1. fázis· H e x a l AG· Forrás
Lezárult
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06333860· 4. fázis· AbbVie· Forrás
Leállították
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573· 2/3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· 3. fázis· Incyte Corporation· Forrás
Lezárult
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC
2023-505145-93-00· 1/2. fázis· Alentis Therapeutics AG· Forrás
Lezárult
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· 2. fázis· Ascendis Pharma Oncology Division A/S· Forrás
Lezárult
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
NCT06058741· AbbVie· Forrás
Toboroz
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
NCT06145373· 4. fázis· Sanofi· Forrás
Toboroz
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
NCT05934084· Fondazione Italiana Linfomi - ETS· Forrás
Lezárult
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· 2. fázis· Sanofi· Forrás
Lezárult
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586· 2. fázis· Cardurion Pharmaceuticals, Inc.· Forrás
Lezárult
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· 2. fázis· Pfizer· Forrás
Lezárult
SafeHeal Diverting Ileostomy Pivotal Study
NCT06152276· SafeHeal Inc· Forrás
Visszavonták
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05966233· 2. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Leállították
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
NCT06039384· 1. fázis· Incyte Corporation· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
NCT06181435· 3. fázis· Sanofi· Forrás
Lezárult
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma
NCT06018129· 1/2. fázis· Genmab A/S· Forrás
Lezárult
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· 1/2. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
2022-503005-38-00· 2. fázis· Landos Biopharma Inc.· Forrás
Lezárult
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961· Novo Nordisk A/S· Forrás
Lezárult
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693· 3. fázis· Mineralys Therapeutics Inc.· Forrás
Lezárult
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer
NCT05724602· 2. fázis· European Organisation For Research And Treatment Of Cancer· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· 3. fázis· Takeda· Forrás
Lezárult
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.
2022-502789-26-01· 2. fázis· Agomab Spain S.L.U.· Forrás
Lezárult
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
NCT06581549· Istituto Oncologico Veneto IRCCS· Forrás
Lezárult
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· 3. fázis· Amgen Inc.· Forrás
Toboroz
Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER)
2022-502060-21-00· 4. fázis· Octapharma AG· Forrás
Lezárult
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00· 1/2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Lezárult
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
2022-502888-38-00· 2. fázis· Eli Lilly & Co.· Forrás
Fut, nem toboroz
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· 2. fázis· BeiGene· Forrás
Fut, nem toboroz
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
NCT05910528· 2. fázis· Hoffmann-La Roche· Forrás
Lezárult
An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
2022-502921-16-00· 4. fázis· Swedish Orphan Biovitrum AB (publ)· Forrás
Fut, nem toboroz
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· 3. fázis· Mineralys Therapeutics Inc.· Forrás
Lezárult
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· 2. fázis· Sanofi· Forrás
Lezárult
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
NCT03744468· 1/2. fázis· Beigene Ltd.· Forrás
Lezárult
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· 4. fázis· AbbVie· Forrás
Lezárult
AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease
NCT05471245· Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS· Forrás
Lezárult
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
NCT05784597· 1. fázis· Philogen S.p.A.· Forrás
Leállították
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NCT05785715· 2. fázis· AbbVie· Forrás

Showing 50 of 160.

Regiszterbeli névváltozatok (88)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

Humanitas Research Hospital
Rozzano, 20089
219 vizsgálat
Istituto Clinico Humanitas
Rozzano, 20089
72 vizsgálat
IRCCS Istituto Clinico Humanitas
Rozzano, 20089
26 vizsgálat
IRCCS Humanitas Research Hospital
Rozzano, Milan 20089
17 vizsgálat
Istituto Clinico Humanitas
Milan, 20089
14 vizsgálat
Istituto Clinico Humanitas
Rozzano (MI), Lombardy 20089
7 vizsgálat
IRCCS Istituto Clinico Humanitas
Milan, 20089
6 vizsgálat
Istituto Clinico Humanitas - U.O. Ematologia
Rozzano
5 vizsgálat
IRCCS Istituto Clinico Humanitas
Rozzano MI, 20089
4 vizsgálat
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas
Rozzano, Milan 20089
4 vizsgálat
IRCCS Humanitas Research Hospital
Milan, 20089
3 vizsgálat
- NCT07927777Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.
  Contact: Buffi Nicolò, MD
- NCT06906094Prevention of Post mEniscectomy Osteoarthritis: From New Animal Model to Patient pRofiLing
- NCT07265414DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
Humanitas Research Hospital IRCCS
Rozzano, 20089
2 vizsgálat
- NCT06955442Racial Disparities in Acute Stroke
- NCT05339841Italian Digital Primary Cardiovascular Prevention Study
IRCCS Humanitas Research Hospital
Rozzano MI, 20089
2 vizsgálat
- 2025-522084-15-00A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
- NCT06977581A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
IRCCS Istituto Clinico Humanitas, Cancer Center
Rozzano, 20089
2 vizsgálat
- NCT05983432Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  Contact: Matteo Simonelli
- NCT02841540A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
UOC di Endocrinologia, Diabetologia e Andrologia Medica, IRCCS Humanitas Research Hospital
Rozzano
2 vizsgálat
- NCT06790251Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)
  Contact: Maria Luisa Brandi, MD, PhD
- NCT06645951Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma
  Contact: Andrea Gerardo Antonio Lania, MD
3800056 - Istituto Clinico Humanitas
Rozzano, 20089
1 vizsgálat
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Endoscopy Unit, Gastroenterology Department, Humanitas Research Hospital
Rozzano, Milano 20089
1 vizsgálat
- NCT06420843Microbiota, Metabolome and Nutrition: an 'Artificially Intelligent' Way to Personalized Nutrition
Gruppo Humanitas - Humanitas Research Hospital (Istituto Clinico Humanitas)
Rozzano, 20089
1 vizsgálat
- NCT06153693Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Humanitas Research Hospital - Medical Oncology
Rozzano, 20089
1 vizsgálat
- NCT05015010Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
Humanitas Research Hospital (Site 1309)
Rozzano, Lombardy 20089
1 vizsgálat
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Humanitas Research Hospital (Site 1600)
Rozzano, Lombardy 20089
1 vizsgálat
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Instituto Clinico Humanitas
Milan
1 vizsgálat
- NCT06414265Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation
  Contact: Antonio Mangieri (principal investigator)
Instituto Clinico Humanitas
Rozzano, Lombardy 20089
1 vizsgálat
- NCT04394546CHAMPION-AF Clinical Trial
Instituto Clinico Humanitas
Rozzano (MI), Lombardy 20089
1 vizsgálat
- NCT02784171Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Instituto Clinico Humanitas Irccs
Rozzano, 20098
1 vizsgálat
- NCT06188702S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University,
Rozzano, Milano
1 vizsgálat
- NCT04102774Effect of AIRVO Heated Humidification in Bronchiectasis
IRCCS Istituto Clinico Humanitas - Dermatology Unit
Rozzano, Lombardy 20089
1 vizsgálat
- NCT07336641LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
  Contact: Antonio Costanzo, MD
IRCCS Istituto clinico humanitas - Humanitas Mirasole spa
Rozzano, 20089
1 vizsgálat
- NCT06430866Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
IRCCS Istituto Clinico Humanitas /ID# 141382
Rozzano, Lombardy 20089
1 vizsgálat
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
IRCCS Istituto Clinico Humanitas /ID# 218560
Rozzano, Lombardy 20089
1 vizsgálat
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
IRCCS Istituto Clinico Humanitas /ID# 251275
Rozzano, Lombardy 20089
1 vizsgálat
- NCT05616871An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis
IRCCS Istituto Clinico Humanitas /ID# 251493
Rozzano, Milano 20089
1 vizsgálat
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
IRCCS Istituto Clinico Humanitas /ID# 259300
Rozzano, Lombardy 20089
1 vizsgálat
- NCT06058741A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
IRCCS Istituto Clinico Humanitas /ID# 260801
Rozzano, Lombardy 20089
1 vizsgálat
- NCT05494606An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
IRCCS Istituto Clinico Humanitas /ID# 262991
Rozzano, Lombardy 20089
1 vizsgálat
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
IRCCS Istituto Clinico Humanitas /ID# 264463
Rozzano, Lombardy 20089
1 vizsgálat
- NCT06764693An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
  Contact: Shari Chapman
IRCCS Istituto Clinico Humanitas /ID# 268731
Rozzano, Lombardy 20089
1 vizsgálat
- NCT05930275Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
IRCCS Istituto Clinico Humanitas /ID# 274489
Rozzano, Lombardy 20089
1 vizsgálat
- NCT07073079A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
  Contact: Caterina Golotta
Istituto Clinico Humanitas /ID# 227943
Rozzano, Milano 20089
1 vizsgálat
- NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Istituto Clinico Humanitas - IRCCS
Milan, 20089
1 vizsgálat
- NCT03647124A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Istituto Clinico Humanitas (Site 1476)
Rozzano, Milano 20089
1 vizsgálat
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Study Coordinator
Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia
Rozzano
1 vizsgálat
- NCT03815643Avelumab Program Rollover Study
Istituto Clinico Humanitas - U.O. Ematologia
Rozzano (MI)
1 vizsgálat
- NCT03159897FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Rozzano, Lombardy 20089
1 vizsgálat
- NCT03452137A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Medicina interna ed epatologia, Istituto clinico Humanitas
Rozzano
1 vizsgálat
- NCT05151809National Database on Primary Biliary Cholangitis
  Contact: Pietro Invernizzi, MD
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
Rozzano, Milano 20089
1 vizsgálat
- NCT06625216Severe Asthma Network Italy
  Contact: Enrico Marco Heffler, MD, PhD
Università Humanitas University - Hunimed (IRCCS Istituto Clinico Humanitas - Humanitas Mirasole S.p.A.)
Rozzano
1 vizsgálat
- NCT06547827Rehabilitation With and Without Robot and Allied Digital Technologies in Stroke Patients
  Contact: Alessio Baricich
U.O di Oncologia Medica ed Ematologia, Humanitas Research Hospital
Rozzano
1 vizsgálat
- NCT05977673Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
  Contact: Francesca Ricci, MD
U.O. Ematologia - Istituto Clinico Humanitas
Rozzano, 20089
1 vizsgálat
- NCT04600804The Role of 18F-FDG-PET for Staging and Prognostication
Gruppo Humanitas - Humanitas Research Hospital - Cancer Center
Rozzano, 20089
Gruppo Humanitas - Humanitas Research Hospital (Instituto Clinico Humanitas)
Rozzano, Lombardy 20089
Gruppo Humanitas - Istituto Clinico Humanitas
Rozzano, 20089
IRCCS Instituto Clinico Humanitas
Rozzano, 20089
IRCCS Istituto Clinico Humanitas /ID# 151363
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 155626
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 155642
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 168153
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 220815
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 246630
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 256684
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 257500
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 260887
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 263466
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 263503
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 265946
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 269473
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 273566
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 274518
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 278458
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas - Rheumatology
Rozzano, 20089
Istituto Clinico Humanitas - Cancer Center (Site 0555)
Rozzano, Milano 20089
Istituto Clinico Humanitas - Humanitas Mirasole SPA
Rozzano, Milan 20089
Istituto Clinico Humanitas /ID# 147528
Rozzano, Milano 20089
Istituto Clinico Humanitas /ID# 200739
Rozzano, Milano 20089
Istituto Clinico Humanitas IRCCS
Rozzano, 20089
Istituto Clinico Humanitas- IRCCS (Site 1902)
Rozzano, Milano 20089
Istituto Clinico Humanitas - Pneumologia 1
Rozzano, 20089
Istituto Clinico Humanitas, Rozzano
Milan, 20159
Istituto Clinico Humanitas Rozzano, IRCCS
Rozzano, 20089
Istituto Clinico Humanitas (Site 0398)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 0504)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 0704)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 1613)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 1803)
Rozzano, Lombardy 20089
Istituto Clinico Humanitas (Site 1808)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 1812)
Rozzano, Milano 20089
Istituto Clinico Humanitas, UO Ematologia
Rozzano
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas
Milan, 20089

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Máj- és epeúti rák121 munka · 23 vizsgálat
Vastagbélrák94 munka · 32 vizsgálat
Asztma90 munka · 4 vizsgálat
Prosztatarák65 munka · 20 vizsgálat
Colitis ulcerosa63 munka · 28 vizsgálat
Bronchiectasis59 munka · 6 vizsgálat
Hólyagrák48 munka · 12 vizsgálat
Crohn-betegség45 munka · 17 vizsgálat
Hasnyálmirigyrák41 munka · 11 vizsgálat
Atópiás dermatitisz (ekcéma)33 munka · 11 vizsgálat
Pikkelysömör33 munka · 11 vizsgálat
Koszorúér-betegség32 munka · 5 vizsgálat
Neuroendokrin daganatok29 munka · 5 vizsgálat
Szisztémás szklerózis (szkleroderma)27 munka · 1 vizsgálat
Szarkóma25 munka · 11 vizsgálat
Primer biliáris cholangitis (PBC)20 munka · 3 vizsgálat
Mielodiszplasztikus szindróma (MDS)19 munka · 13 vizsgálat
Hemofília17 munka · 8 vizsgálat
Aortic stenosis16 munka · 1 vizsgálat
Arthritis psoriatica15 munka · 5 vizsgálat
Hodgkin-limfóma14 munka · 8 vizsgálat
Fej-nyaki daganatok12 munka · 19 vizsgálat
Mezotelióma11 munka · 8 vizsgálat
Myocarditis9 munka · 1 vizsgálat
Dilated cardiomyopathy9 munka · 3 vizsgálat
Alopecia areata7 munka · 3 vizsgálat
Köpenysejtes limfóma6 munka · 7 vizsgálat
Dystonia6 munka · 1 vizsgálat
Coeliac disease5 munka · 0 vizsgálat
Trigeminal neuralgia4 munka · 1 vizsgálat

Intézményadatok: ROR 05d538656 (CC0-1.0)Frissítve: 2026. nov. 12.

Hibát jelzek